Search research articles
Contact Us
Filters
Showing results (201-210 of 218) with videos related to
Page
of 22
Sort By:
British Journal of Cancer
|
July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, et al.
American Journal of Medical Genetics. Part A
|
November 15, 2015
Craniosynostosis in 10q26 deletion patients: A consequence of brain underdevelopment or altered suture biology?
Ágatha Cristhina Faria, Eliete Rabbi-Bortolini, Maria R G O Rebouças, et al.
The Pharmacogenomics Journal
|
December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
F Graziano, A Ruzzo, E Canestrari, et al.
Breast Cancer Research and Treatment
|
February 23, 2026
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis
L Sisca, M G Polito, M Silletta, et al.
The Pharmacogenomics Journal
|
June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A Ruzzo, F Graziano, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
S Cascinu, F Graziano, F Ferraù, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
December 22, 2009
A survey on Prader-Willi syndrome in the Italian population: prevalence of historical and clinical signs
A Crinò, G Di Giorgio, C Livieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
E Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Open
|
August 21, 2025
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
A R Filippi, M R García Campelo, J-B Paoli, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 218) with videos related to
Sort By:
Page
of 22
British Journal of Cancer
|
July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, et al.
American Journal of Medical Genetics. Part A
|
November 15, 2015
Craniosynostosis in 10q26 deletion patients: A consequence of brain underdevelopment or altered suture biology?
Ágatha Cristhina Faria, Eliete Rabbi-Bortolini, Maria R G O Rebouças, et al.
The Pharmacogenomics Journal
|
December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
F Graziano, A Ruzzo, E Canestrari, et al.
Breast Cancer Research and Treatment
|
February 23, 2026
Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis
L Sisca, M G Polito, M Silletta, et al.
The Pharmacogenomics Journal
|
June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A Ruzzo, F Graziano, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
S Cascinu, F Graziano, F Ferraù, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
C Cremolini, C Antoniotti, S Lonardi, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
December 22, 2009
A survey on Prader-Willi syndrome in the Italian population: prevalence of historical and clinical signs
A Crinò, G Di Giorgio, C Livieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
E Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Open
|
August 21, 2025
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
A R Filippi, M R García Campelo, J-B Paoli, et al.
Page
of 22